12 May 2017Americas

Amgen sets sights on Coherus over biologic drug

Amgen has set its sights on Coherus Biosciences, a biosimilar maker, for allegedly infringing a patent concerning a process for purifying proteins.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

US court dismisses Amgen biologic patent suit

28 March 2018 A Delaware court has dismissed a patent infringement claim brought by Amgen against a biosimilar maker.

Americas

Federal Circuit dismisses Amgen’s Neulasta appeal

30 July 2019 California-based Amgen is barred from succeeding on its patent infringement claim against Coherus Biosciences, according to the US Court of Appeals for the Federal Circuit.

Big Pharma

Coherus secures toripalimab rights for US and Canada

4 February 2021 Coherus Biosciences has signed a deal with Chinese biopharmaceutical company Shanghai Junshi Biosciences for the development and commercialisation rights to toripalimab, Junshi’s PD-1 inhibitor, in the US and Canada.

More on this story

Americas

US court dismisses Amgen biologic patent suit

28 March 2018 A Delaware court has dismissed a patent infringement claim brought by Amgen against a biosimilar maker.

Americas

Federal Circuit dismisses Amgen’s Neulasta appeal

30 July 2019 California-based Amgen is barred from succeeding on its patent infringement claim against Coherus Biosciences, according to the US Court of Appeals for the Federal Circuit.

Big Pharma

Coherus secures toripalimab rights for US and Canada

More on this story

Americas

US court dismisses Amgen biologic patent suit

28 March 2018 A Delaware court has dismissed a patent infringement claim brought by Amgen against a biosimilar maker.

Americas

Federal Circuit dismisses Amgen’s Neulasta appeal

30 July 2019 California-based Amgen is barred from succeeding on its patent infringement claim against Coherus Biosciences, according to the US Court of Appeals for the Federal Circuit.

Big Pharma

Coherus secures toripalimab rights for US and Canada